Sex hormones and lipoprotein(a) concentration

Expert Opinion on Investigational Drugs

Volumn 20, Issue 2, 2011, Pages 221-238

  Gaeta, Giovanni ^a   Lanero, Simona ^a   Barra, Silvia ^a   Silvestri, Nunzia ^a   Cuomo, Vittoria ^b   Materazzi, Crescenzo ^a   Vitagliano, Giancarlo ^a  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

androgens; estrogens; lipoprotein(a); SERMs

Indexed keywords

ANDROGEN; ANTIANDROGEN; CETRORELIX; CHORIONIC GONADOTROPIN; CONJUGATED ESTROGEN; DANAZOL; ESTRADIOL; ESTRADIOL VALERATE; ETHINYLESTRADIOL; FOSFESTROL; GOSERELIN; HUMAN MENOPAUSAL GONADOTROPIN; LIPOPROTEIN A; MEDROXYPROGESTERONE ACETATE; NANDROLONE DECANOATE; NORETHISTERONE ACETATE; POLYESTRADIOL PHOSPHATE; PRASTERONE; PROGESTERONE; SEX HORMONE; STANOZOLOL; TAMOXIFEN; TESTOLACTONE; TESTOSTERONE; TESTOSTERONE DECANOATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TIBOLONE; TOREMIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DISULFIDE BOND; DRUG BIOAVAILABILITY; DYSLIPIDEMIA; ENDOMETRIOSIS; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; HEMODIALYSIS; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPOGONADOTROPIC HYPOGONADISM; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; KLINEFELTER SYNDROME; LIPID METABOLISM; LIPOLYSIS; LOADING DRUG DOSE; METASTASIS; NONHUMAN; ORAL CONTRACEPTION; ORCHIECTOMY; OSTEOPOROSIS; OVARIECTOMY; PATHOPHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN DOMAIN; PROTEIN STRUCTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM; THERAPY EFFECT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ESTROGENS; FEMALE; HUMANS; LIPOPROTEIN(A); SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79951940124     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.548804     Document Type: Review

References (175)

1. Berg K. A new serum type system in man: the Lp(a) system. Acta Pathol Microbiol Scand 1963;59(Suppl):369-82.
2. Kiechl S, Willeit J. The mysteries of lipoprotein(a) and cardiovascular disease revisited. J Am Coll Cardiol 2010;55:2168-70.
3. Utermann G. Lp(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular basis of inherited disease. McGraw Hill, Inc., New York; 1995. p. 1887-912.
4. Acquati F, Hammer R, Ercoli B, et al. Transgenic mice expressing a human apolipoprotein[a] allele. J Lipid Res 1999;40:994-1006. (Pubitemid 29287870)
5. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
6. Kraft HG, Kochl S, Menzel HJ, et al. The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992;90:220-30.
7. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol 1999;10:133-41. (Pubitemid 29187096)
8. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
9. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-9.
10. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-28.
11. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
12. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008;168:598-608. (Pubitemid 351468395)
13. Nordestgaard BG, Chapman MJ, Ray K, et al.; For the European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J.[ Epub ahead of print].
14. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004;37:333-43. (Pubitemid 38490450)
15. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7. (Pubitemid 17158542)
16. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993;87:1135-41. (Pubitemid 23110386)
17. Hancock MA, Boffa MB, Marcovina SM, et al. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003;278:23260-9. (Pubitemid 36830139)
18. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-92. (Pubitemid 19236892)
19. Yamada S, Morishita R, Nakamura S, et al. Development of antibody against epitope of lipoprotein(a) modified by oxidation: evaluation of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a). Circulation 2000;102:1639-44.
20. Romero FI, Khamashta MA, Hughes GR. Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis. Lupus 2000;9:206-9. (Pubitemid 30199264)
21. Grainger DJ, Kemp PR, Liu AC, et al. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature 1994;370:460-2. (Pubitemid 24263550)
22. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008;19:369-77.
23. Haque NS, Zhang X, French DL, et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000;102:786-92. (Pubitemid 30643286)
24. Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998;97:721-8. (Pubitemid 28135333)
25. Zhao SP, Xu DY. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res 2000;100:501-10.
26. Schachinger V, Halle M, Minners J, et al. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1997;30:927-34. (Pubitemid 27435883)
27. Bermudez V, Arraiz N, Aparicio D, et al. Lipoprotein(a): from molecules to therapeutics. Am J Ther 2010;17:263-73.
28. Zysow BR, Kauser K, Lawn RM, Rubanyi GM. Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice. Arterioscler Thromb Vasc Biol 1997;17:1741-5. (Pubitemid 27423996)
29. Frazer KA, Narla G, Zhang JL, Rubin EM. The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice. Nat Genet 1995;9:424-31.
30. Lawn RM. How often has Lp(a) evolved? Clin Genet 1996;49:167-74. (Pubitemid 26237098)
31. Huby T, Afzal V, Doucet C, et al. Regulation of the expression of the apolipoprotein(a) gene: evidence for a regulatory role of the 5¢ distal apolipoprotein(a) transcription control region enhancer in yeast artificial chromosome transgenic mice. Arterioscler Thromb Vasc Biol 2003;23:1633-9. (Pubitemid 37108209)
32. Wang J, Boedeker J, Hobbs HH, White AL. Determinants of human apolipoprotein [a] secretion from mouse hepatocyte cultures. J Lipid Res 2001;42:60-9. (Pubitemid 32143760)
33. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-40. (Pubitemid 23216624)
34. Becker L, Webb BA, Chitayat S, et al. A ligand-induced conformational change in apolipoprotein(a) enhances covalent Lp(a) formation. J Biol Chem 2003;278:14074-81. (Pubitemid 36799953)
35. White AL, Guerra B, Lanford RE. Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum. J Biol Chem 1997;272:5048-55. (Pubitemid 27090058)
36. Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J Clin Invest 1993;91:1630-6. (Pubitemid 23127366)
37. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
38. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Turnover of lipoprotein (a) in man. J Clin Invest 1980;65:1483-90. (Pubitemid 10122391)
39. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994;93:2758-63.
40. Bonen DK, Hausman AM, Hadjiagapiou C, et al. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 1997;272:5659-67. (Pubitemid 27102393)
41. Kraft HG, Menzel HJ, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137-42. (Pubitemid 19048415)
42. Trieu VN, McConathy WJ. A two-step model for lipoprotein(a) formation. J Biol Chem 1995;270:15471-4.
43. Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005;46:2681-91. (Pubitemid 43107480)
44. Jialal I. Evolving lipoprotein risk factors: lipoprotein(a) and oxidized low-density lipoprotein. Clin Chem 1998;44:1827-32. (Pubitemid 28368903)
45. Rouy D, Duverger N, Lin SD, et al. Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. Lipoprotein(a) assembly with human and rabbit apolipoprotein B. J Biol Chem 1998;273:1247-51. (Pubitemid 28049228)
46. Marcovina SM, Lippi G, Bagatell CJ, Bremner WJ. Testosterone-induced suppression of lipoprotein(a) in normal men; relation to basal lipoprotein(a) level. Atherosclerosis 1996;122:89-95.
47. Henriksson P, Angelin B, Berglund L. Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992;89:1166-71.
48. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-76. (Pubitemid 41428540)
49. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31. (Pubitemid 32207487)
50. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98. (Pubitemid 34158223)
51. Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 2004;151:415-24. (Pubitemid 39430256)
52. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5. (Pubitemid 44232378)
53. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: european prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701. (Pubitemid 350291241)
54. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
55. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010;31:1494-501.
56. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.
57. Snyder PJ. In: Hardman JG, Limbird LE, editors, Goodman and Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw Hill, New York; 2001. p. 1635-45.
58. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008;154:502-21. (Pubitemid 351744954)
59. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging 2009;4:397-412.
60. Brawer MK. Testosterone replacement in men with andropause: an overview. Rev Urol 2004;6(Suppl 6):S9-15.
61. Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, Gilman AG, editors, Goodman & Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw-Hill, New York;. p. 1597-635.
62. Haffner SM, Mykkanen L, Gruber KK, et al. Lack of association between sex hormones and Lp(a) concentrations in American and Finnish men. Arterioscler Thromb 1994;14:19-24.
63. Denti L, Pasolini G, Ablondi F, Valenti G. Correlation between plasma lipoprotein Lp(a) and sex hormone concentrations: a cross-sectional study in healthy males. Horm Metab Res 1994;26:602-8. (Pubitemid 24381121)
64. Davoodi G, Amirezadegan A, Borumand MA, et al. The relationship between level of androgenic hormones and coronary artery disease in men. Cardiovasc J Afr 2007;18:362-6. (Pubitemid 351300619)
65. Noyan V, Yucel A, Sagsoz N. The association of androgenic sex steroids with serum lipid levels in postmenopausal women. Acta Obstet Gynecol Scand 2004;83:487-90. (Pubitemid 38534770)
66. Lambrinoudaki I, Christodoulakos G, Rizos D, et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 2006;154:907-16. (Pubitemid 43997731)
67. Anderson RA, Wallace EM, Wu FC. Effect of testosterone enanthate on serum lipoproteins in man. Contraception 1995;52:115-19.
68. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. Am J Cardiol 1996;77:1244-7. (Pubitemid 26186973)
69. Ozata M, Yildirimkaya M, Bulur M, et al. Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996;81:3372-8. (Pubitemid 26296218)
70. Zang H, Carlstrom K, Arner P, Hirschberg AL. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil Steril 2006;86:136-44. (Pubitemid 43962962)
71. Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999;84:3896-902. (Pubitemid 30644171)
72. Floter A, Nathorst-Boos J, Carlstrom K, Von Schoultz B. Serum lipids in oophorectomized women during estrogen and testosterone replacement therapy. Maturitas 2004;47:123-9. (Pubitemid 38130194)
73. Teruel JL, Lasuncion MA, Rivera M, et al. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997;29:569-75. (Pubitemid 27155279)
74. Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein(a). Br J Sports Med 2004;38:253-9. (Pubitemid 38748112)
75. Hislop MS, St Clair Gibson A, Lambert MI, et al. Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis 2001;159:425-32. (Pubitemid 33127256)
76. Albers JJ, Taggart HM, Applebaum-Bowden D, et al. Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 1984;795:293-6. (Pubitemid 14006617)
77. Crook D, Sidhu M, Seed M, et al. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992;92:41-7.
78. Von Eckardstein A, Kliesch S, Nieschlag E, et al. Suppression of endogenous testosterone in young men increases serum levels of high density lipoprotein subclass lipoprotein A-I and lipoprotein(a). J Clin Endocrinol Metab 1997;82:3367-72. (Pubitemid 27419089)
79. Berglund L, Carlstrom K, Stege R, et al. Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996;81:2633-7. (Pubitemid 26240289)
80. Denti L, Pasolini G, Cortellini P, et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem 1996;42(8 Pt 1):1176-81. (Pubitemid 26260334)
81. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53. (Pubitemid 18045752)
82. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-55.
83. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
84. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
85. Sutherland RL, Murphy LC, San Foo M, et al. High-affinity antioestrogen binding site distinct from the oestrogen receptor. Nature 1980;288:273-5. (Pubitemid 11165875)
86. De Medina P, Silvente-Poirot S, Poirot M. Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 2009;5:1066-7.
87. Kedjouar B, De Medina P, Oulad-Abdelghani M, et al. Molecular characterization of the microsomial tamoxifen binding site. J Biol Chem 2004;279:34048-61. (Pubitemid 39063057)
88. De Medina P, Favre G, Poirot M. Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anti Cancer Agents 2004;4:491-508. (Pubitemid 39406262)
89. De Medina P, Payre BL, Bernad J, et al. Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 2004;308:1165-73. (Pubitemid 38263994)
90. Eisen A, Trudeau M, Shelley W, et al. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008;34:157-74.
91. Hiraga T, Shimokawa K, Murase T, Yokoyama M. Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer. Endocr J 1993;40:507-13. (Pubitemid 24019868)
92. Usui S, Suzuki K, Yamanaka H, et al. Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques. Clin Chim Acta 2002;317:133-43. (Pubitemid 34114028)
93. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein(a) concentrations in postmenopausal women taking norethisterone. BMJ 1991;303:694.
94. Mendoza S, Velazquez E, Osona A, et al. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein[a]. J Lab Clin Med 1994;123:837-41.
95. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14:1586-93.
96. Kim CJ, Jang HC, Cho DH, et al. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81. (Pubitemid 124004436)
97. Kim CJ, Min YK, Ryu WS, et al. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 1996;156:1693-700. (Pubitemid 26287126)
98. Schram JH, Boerrigter PJ, The TY. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism. Maturitas 1995;22:121-30.
99. Taskinen MR, Puolakka J, Pyorala T, et al. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. Arterioscler Thromb Vasc Biol 1996;16:1215-21. (Pubitemid 26339708)
100. Hanggi W, Lippuner K, Riesen W, et al. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study. Br J Obstet Gynaecol 1997;104:708-17. (Pubitemid 27278355)
101. Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 1997;17:1822-9. (Pubitemid 27424007)
102. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
103. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998;97:979-86. (Pubitemid 28125470)
104. Farish E, Barnes JF, Fletcher CD, et al. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Menopause 1999;6:98-104. (Pubitemid 29266667)
105. Mijatovic V, van der Mooren MJ, Kenemans P, et al. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999;6:134-7. (Pubitemid 29266672)
106. Abbey M, Owen A, Suzakawa M, et al. Effects of menopause and hormone replacement therapy on plasma lipids, lipoproteins and LDL-receptor activity. Maturitas 1999;33:259-69.
107. Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52. (Pubitemid 30207621)
108. Seed M, Sands RH, McLaren M, et al. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam Pract 2000;17:497-507. (Pubitemid 32007706)
109. Ossewaarde ME, Bots ML, Bak AA, et al. Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women. Maturitas 2001;39:209-16. (Pubitemid 32900550)
110. Falco C, Tormo G, Estelles A, et al. Fibrinolysis and lipoprotein(a) in women with coronary artery disease. Influence of hormone replacement therapy. Haematologica 2001;86:92-8. (Pubitemid 32147057)
111. Smolders RG, Vogelvang TE, Mijatovic V, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas 2002;41:105-14. (Pubitemid 34142499)
112. Perry W, Wiseman RA. Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry. Maturitas 2002;42:157-64. (Pubitemid 34628400)
113. Gregoriou O, Christodoulakos G, Siristatidis C, et al. Continuous combined replacement therapy in postmenopausal women: effect on plasma lipoproteins, bone mass and the endometrium. Hormones (Athens) 2002;1:239-44.
114. Prelevic GM, Kwong P, Byrne DJ, et al. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945-51. (Pubitemid 34497161)
115. Kwok S, Selby PL, McElduff P, et al. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol (Oxf) 2004;61:760-7. (Pubitemid 40006798)
116. Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, et al. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women. Gynecol Endocrinol 2004;18:244-57. (Pubitemid 38746359)
117. Bukowska H, Stanosz S, Zochowska E, et al. Does the type of hormone replacement therapy affect lipoprotein(a), homocysteine, and C-reactive protein levels in postmenopausal women? Metabolism 2005;54:72-8. (Pubitemid 39572460)
118. Ko HS, Kim CJ, Ryu WS. Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women. Korean J Intern Med 2005;20:33-9. (Pubitemid 40724344)
119. Bayrak A, Aldemir DA, Bayrak T, et al. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet 2006;274:289-96. (Pubitemid 44127293)
120. Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. J Thromb Haemost 2008;6:928-34. (Pubitemid 351689913)
121. Perrone G, Capri O, Galoppi P, et al. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. Gynecol Obstet Invest 2009;68:33-9.
122. Perrone G, Stefanutti C, Galoppi P, et al. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia. Int J Fertil Menopausal Stud 1996;41:509-15. (Pubitemid 27044432)
123. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601. (Pubitemid 27360759)
124. Decensi A, Robertson C, Ballardini B, et al. Effect of tamoxifen on lipoprotein (a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 1999;35:596-600. (Pubitemid 29192968)
125. Shewmon DA, Stock JL, Abusamra LC, et al. Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism 1994;43:531-2. (Pubitemid 24145455)
126. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33. (Pubitemid 26051003)
127. Liberopoulos E, Karabina SA, Tselepis A, et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 2002;62(2):115-20. (Pubitemid 34253080)
128. Kusama M, Miyauchi K, Aoyama H, et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 2004;88:1-8. (Pubitemid 39524439)
129. Elisaf MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510-13. (Pubitemid 32744681)
130. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005;16:707-15. (Pubitemid 40767090)
131. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol (Copenh) 1993;128:259-62. (Pubitemid 23100883)
132. Farish E, Barnes JF, Rolton HA, et al. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994;20:215-19.
133. Kalogeropoulos S, Petrogiannopoulos C, Gagos S, et al. The influence of 5-year therapy with tibolone on the lipid profile in postmenopausal women with mild hypercholesterolemia. Gynecol Endocrinol 2004;18:227-32. (Pubitemid 38510013)
134. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-6. (Pubitemid 19230908)
135. Scanu AM, Bamba R. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations. Am J Cardiol 2008;101(Suppl):B44-7.
136. Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 1991;337:612.
137. Melichar B, Kalabova H, Krcmova L, et al. Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res 2009;29:3337-46.
138. Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol 2007;166:511-17. (Pubitemid 47283647)
139. Cheung MC, Albers JJ, Wahl PW, Hazzard WR. High density lipoproteins during hypolipidemic therapy. A comparative study of four drugs. Atherosclerosis 1980;35:215-28. (Pubitemid 10174121)
140. Taggart HM, Applebaum-Bowden D, Haffner S, et al. Reduction in high density lipoproteins by anabolic steroid (stanozolol) therapy for postmenopausal osteoporosis. Metabolism 1982;31:1147-52. (Pubitemid 13233919)
141. Jockenhovel F, Bullmann C, Schubert M, et al. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 1999;48:590-6. (Pubitemid 29230519)
142. Schaefer EJ, Foster DM, Zech LA, et al. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262-7. (Pubitemid 13032472)
143. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204.
144. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9. (Pubitemid 24330218)
145. Morales M, Santana N, Soria A, et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 1996;40:265-70. (Pubitemid 26336122)
146. Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-5. (Pubitemid 28501035)
147. Kataja V, Hietanen P, Joensuu H, et al. The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer - a randomised study. Breast Cancer Res Treat 2002;76(Suppl 1):S156.
148. Wojtacki J, Lesniewski-Kmak K, Pawlak W, et al. Anastrozole therapy and lipid profile: an update [abstract 297]. Eur J Cancer 2004;40(Suppl 2):142.
149. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26. (Pubitemid 33020511)
150. Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6. (Pubitemid 127495180)
151. Tenover L. The androgen-deficient aging male: current treatment options. Rev Urol 2003;5(Suppl 1):S22-8.
152. Bagatell CJ, Bremner WJ. Androgens in men - uses and abuses. N Engl J Med 1996;334:707-14. (Pubitemid 26079806)
153. Reyes-Fuentes A, Veldhuis JD. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol Metab Clin North Am 1993;22:93-124. (Pubitemid 23079403)
154. Menon DK. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 2003;79(Suppl 3):1659-61. (Pubitemid 36687950)
155. Brower KJ. Anabolic steroid abuse and dependence. Curr Psychiatry Rep 2002;4:377-87.
156. Thiblin I, Runeson B, Rajs J. Anabolic androgenic steroids and suicide. Ann Clin Psychiatry 1999;11:223-31.
157. Brawer MK. Testosterone replacement therapy in men with andropause: an overview. Rev Urol 2004;6(Suppl 6):S9-15.
158. Raynaud JP. Testosterone deficiency syndrome: treatment and cancer risk. J Steroid Biochem Mol Biol 2009;114:96-105.
159. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.
160. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32. (Pubitemid 26274121)
161. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
162. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44. (Pubitemid 29165190)
163. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32. (Pubitemid 30117736)
164. Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600. (Pubitemid 34760816)
165. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-15. (Pubitemid 44307491)
166. Beral V, Bull D, Reeves G. Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
167. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:139.e1-7.
168. Wu FC, Von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217. (Pubitemid 36515284)
169. Tong PC, Ho CS, Yeung VT, et al. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab 2005;90:6418-23. (Pubitemid 41759294)
170. Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004;109:2074-9. (Pubitemid 38620214)
171. Kanayama G, Brower KJ, Wood RI, et al. Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend 2010;109:6-13.
172. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638-42. (Pubitemid 32144190)
173. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84. (Pubitemid 37430138)
174. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680-90. (Pubitemid 34462681)
175. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80 (Pubitemid 39314963)